I'd check out the poster from the link I provided. While nothing clear cut, lets say I won't be rushing to buy Pipex anytime soon based on these results (I don't follow the company closely enough to comment on its value was just following their IPF program).
Here is the text:
[3:15 pm] A Phase I/II Trial of Tetrathiomolybdate for Patients With Idiopathic Pulmonary Fibrosis Refractory to Previous Therapy, [Publication Page: A497]
K.R. Flaherty, M.D., M.S., G.J. Brewer, M.D., A. Andrei, PhD., S. Murray, ScD., G.B. Toews, M.D., F.J. Martinez, M.D., M., Ann Arbor, MI
Rationale: IPF is a fatal disorder without effective therapy. Tetrathiomolybdate (TM) is an anti-Copper drug developed for the treatment of Wilsons disease. TM is effective in modulating the fibrotic response in a Bleomycin mouse model of pulmonary fibrosis.
Methods: We treated 23 patients with IPF that had evidence of disease progression despite treatment with prednisone +/- cytotoxic therapy with TM for 1 year. Patients were monitored for adverse events, change in pulmonary function and walk distance. When pre-treatment FVC values were available the course of pre-treatment FVC (slope) was compared to the post-treatment FVC at 6 and 12 months.
Results: The initial three patients developed severe nausea and withdrew from the study prior to reaching a therapeutic copper level. In response, the induction dose was modified and TM was well tolerated in the remaining 20 patients. Dose-related nausea and cytopenias were the most common and expected adverse reactions. Three patients did not complete the trial (patient preference n=2, anemia n=1), 2 patients died during the trial. There was no significant change in FVC % predicted between baseline and 12 months (61 + 13 vs 59 + 13, p=0.18, paired t-test). Average walk distance declined from baseline to 12 months of follow up (871 + 358 vs 646 + 444 feet, p = 0.02, paired t-test).
Conclusion: Treatment with TM for patients with IPF was well-tolerated and associated with a trend toward stabilization in FVC. Further exploration of the therapeutic efficacy of TM through a placebo controlled trial is warranted.
Pretreatment - Posttreatment slope FVC % Predicted 6 Month p value 12 Month p value
Pre-Post Trajectory -0.82 + 1.5 0.06 -0.66 + 1.6 0.12
Session Info: [**] Mini-Symposium, [B91] ILD: THERAPEUTIC INTERVENTION
Session Time: 1:30 PM - 4:15 PM
Presentation Time: 3:15 PM
Room: Room 250-262 (West Mezzanine), Moscone Center
AI
